Nuveen California Select Tax-Free Income Portfolio (NXC) Stock Price

12.9706 ▲ +0.0306 (+0.24%)
Open: 12.94 Vol: 13.58K Day's range: 12.935 - 12.9706 Sep 29, 16:00 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
NXC Technical Analysis
5 mins 30 mins Hourly Daily Weekly
BUY BUY BUY BUY BUY
  5 mins 30 mins Hourly Daily Weekly
MA5 12.92▲ 12.92▲ 12.92▲ 12.95▲ 12.94▲
MA10 12.91▲ 12.93▲ 12.94▲ 12.95▲ 12.89▲
MA20 12.93▲ 12.94▲ 12.96▲ 12.93▲ 12.87▲
MA50 12.94▲ 12.92▲ 12.91▲ 12.87▲ 13.03▼
MA100 12.91▲ 12.93▲ 12.93▲ 12.88▲ 13.13▼
MA200 12.89▲ 12.87▲ 12.87▲ 12.95▲ 13.44▼
  5 mins 30 mins Hourly Daily Weekly
MACD 0.001▲ -0.003▼ -0.006▼ -0.003▼ 0.026▲
RSI 58.034▲ 54.781▲ 53.120▲ 55.818▲ 51.975▲
STOCH 45.098     31.373     36.007     40.078     58.862    
WILL %R -11.765▲ -11.765▲ -34.783     -44.420     -46.816    
CCI 83.544     66.944     44.760     -14.889     53.285    
Latest Filters Detected On NXC
MA $NXC Price Crossed Above MA(200) Set Alert
MA $NXC Price Crossed Above MA(13) Set Alert
MA $NXC Price Crossed Above MA(7) Set Alert
CDL $NXC Marubozu Candlestick Pattern Detected Set Alert
Nuveen California Select Tax-Free Income Portfolio News
Wolfspeed rockets more than 1,000% as it switches incorporation from N.C. to Del.
Monday, September 29, 2025 09:14 AM
Wolfspeed (NYSE:WOLF) shares rocketed more than 1,000% during Monday market action to about $15 after closing on Friday at $1.20 as the company officially moved its incorporation from North Carolina ...
Nukkleus regains full Nasdaq compliance
Monday, September 29, 2025 06:20 AM
Nukkleus (NUKK) announced that it has regained full compliance with the Nasdaq Global Market’s minimum market capitalization requirement. The ...
Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2
Thursday, September 18, 2025 10:30 AM
About NEXICART-2 NEXICART-2 (NCT06097832) is an ongoing multi-site U.S. Phase 1/2 clinical trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory AL Amyloidosis, with a registrational ...
NXC historical stock data
date open high low close volume
29/09/25 12.94 12.9706 12.935 12.9706 13,577
26/09/25 12.90 12.94 12.90 12.94 20,700
25/09/25 12.96 12.96 12.87 12.90 46,200
24/09/25 12.95 13.00 12.95 12.97 31,000
23/09/25 12.96 13.01 12.95 12.97 21,800
22/09/25 12.93 13.04 12.93 12.95 30,100
19/09/25 12.94 12.95 12.92 12.93 8,900
18/09/25 12.94 13.00 12.93 12.94 13,100
17/09/25 12.97 13.04 12.93 12.94 28,400
16/09/25 12.97 13.051 12.96 13.01 12,327
Quote Details
52wk Low:12.41
52wk High:14.08
Vol:13.58K
Avg Vol(3m):367.8K
1Y Chng:-7.09%
1M Chng:+1.33%
Add to Watch List
More Information
Index N/A
Market Cap. 82.98M